Evaluation of selective oestrogen receptor modulators [raloxifene] on bone mineral density, serum lipids and uterine endometrium in early postmenopausal women

ABSTRACT

This study was to evaluate the effect of the second generation selective oestrogen receptor modulator [SERMs], raloxifene, on bone mineral density, serum lipid concentrations, and endometrial thickness in 100 postmenopausal women. The women were divided into two equal groups of 50 women each, and were randomly assigned to receive 60 mg of raloxifene or placebo daily for 24 months. This study revealed that women receiving [SERMs], raloxifene had significant increases from base-line values in bone mineral density of the lumbar spine, hip, and. total body, whereas those receiving placebo had decreases in bone mineral density. Serum concentrations of total cholesterol and low-density lipoprotein cholesterol decreased in the raloxifene group, whereas serum concentrations of high-density lipoprotein cholesterol and triglycerides did not change. Endometrial thickness were comparable in the raloxifene and placebo groups at all times during the study. The proportion of women receiving raloxifene who reported hot flashes or vaginal bleeding were not different from that in women receiving placebo. Selective oestrogen receptor modulator [SERMs] Raloxifen at a dose 60mg per/day increases bone mineral density, lowers serum concentration of total and low-density lipoprotein cholesterol, while has no effect on the endometrium or the breast